H.C. Wainwright resumed coverage of NovaBridge (NBP) with a Buy rating and price target of $9, up from $7. The firm says givastomig has the potential to be the best-in-class bispecific antibody in frontline immune chemotherapy combinations.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBP:
- NovaBridge CEO Begins Open-Market Purchases of Company ADSs
- NovaBridge Biosciences Executive Begins Open-Market ADS Purchases
- NovaBridge announces open market purchases by executive chairman Fu Wei
- NovaBridge Biosciences Executive Chairman Begins Up to $5 Million Open-Market ADS Purchase
- Reiterating Buy on NovaBridge: Strong Phase 1b Givastomig Data, Manageable Safety, and Attractive Entry Point Support $9 Target